CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/11/2025 at 07:30, 5 months 23 days ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
BRIEF

published on 06/06/2025 at 17:50, 5 months 28 days ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
BRIEF

published on 06/04/2025 at 20:26, 6 months ago

CROSSJECT launches a capital increase of nearly 5 million euros

Investment Pharmaceutical Capital Increase Preferential Subscription Right ZEPIZURE®
PRESS RELEASE

published on 06/04/2025 at 20:21, 6 months ago

Launch of a capital increase with preferential subscription rights for nearly 5 million euros
CROSSJECT announces capital increase with preferential subscription rights totaling nearly 5 million euros. Existing shareholders and Vatel Capital commit to subscribe 76.4% of the amount. Subscription price set at 1.40 euros. Subscription period from June 12 to June 20, 2025

Capital Increase Subscription Period Preferential Subscription Rights Crossject Vatel Capital
BRIEF

published on 06/03/2025 at 07:35, 6 months 1 day ago

Maxim Group Recommends CROSSJECT with €4.00 Target Price

Buy Recommendation Crossject ZEPIZURE® Needle-free Auto-injector Maxim Group
PRESS RELEASE

published on 06/03/2025 at 07:30, 6 months 1 day ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Maxim Group initiates coverage of CROSSJECT with BUY recommendation and €4.00 target price. CROSSJECT, a specialty pharma company, looks forward to positive developments with FDA and pipeline

FDA Buy Recommendation Specialty Pharma Crossject Maxim Group
BRIEF

published on 05/27/2025 at 07:35, 6 months 8 days ago

CROSSJECT optimizes its production with the ZENEO® Nest

CDMO Funding Production Crossject ZENEO® Nest
BRIEF

published on 05/20/2025 at 07:35, 6 months 15 days ago

CROSSJECT Plans €5 Million Capital Increase to Boost EUA Approval Activities

Capital Increase Crossject ZEPIZURE® Gemmes Venture EUA Approval
PRESS RELEASE

published on 05/20/2025 at 07:30, 6 months 15 days ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 6 months 28 days ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 23 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 28 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 58 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 53 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 58 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 27 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 7 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 32 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 43 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 47 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 58 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 13 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 14 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 57 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE